newsfilter
← Latest News
GlobeNewswire·

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

VTVT
  • vTv Therapeutics Inc. granted 23,500 stock options to two non-executive employees as a material inducement for employment under Nasdaq Listing Rule 5635(c)(4).
  • The stock options carry a weighted average exercise price of $31.95 per share.
  • Each award vests over a 4-year period with 25% vesting on the first anniversary and the remainder vesting quarterly over the following 36 months subject to continued employment.
  • The options have a 10-year term & are governed by the 2026 Inducement Plan.
  • vTv Therapeutics is a late-stage biopharmaceutical company developing cadisegliatin, an oral glucokinase activator in a US Phase 3 trial for type 1 diabetes.
  • Cadisegliatin (TTP399) has received Breakthrough Therapy designation from the FDA.
  • The safety & efficacy of cadisegliatin have not been established, & there is no guarantee of regulatory approval or commercial availability.